Insight Molecular Diagnostics Inc. — Director's Dealing 2019

Jun 3, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2019-05-22

Reporting Person: Sundar Padma (SVP, Marketing & Market Access)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$4.94	2029-05-21	Common Stock (180000)		Direct

Footnotes

F1: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on May 22, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date.